Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| CD7 T-ALL/T-LBL only (~15% of ALL); B-ALL is CD7-negative | >99% | Flow cytometry, median % CD7+ blasts in 49 diagnostic T-ALL samples (incl. 14 ETP-ALL); stable at relapse and during chemotherapy | doi.org |
| CD19 | >95% | B-ALL surface expression | Wikipedia |
| CD22 | >90% | expression on B-ALL blasts | |
| Menin | 5-10% | KMT2A rearrangement (adult); ~70% infant ALL | Wikipedia |
| BCR::ABL1 (Philadelphia chromosome) | ~25 adults; ~3 children% | t(9;22) | |
| Glucocorticoid receptor (NR3C1) | nearly all% | Glucocorticoid receptor expressed in lymphoblasts; prednisone response is a prognostic marker | cancer.gov |
| KMT2A (MLL) rearrangement | ~80 in infants; 5-10 in adults% | rearrangement |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
6 cell lines, 0 mouse models and 2 repositories are listed for this cancer. See them →